Last update 01 Nov 2024

Veltuzumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-CD20 monoclonal antibody, Humanised anti-CD20 monoclonal antibody, Monoclonal antibody hA20
+ [3]
Target
Mechanism
CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), CD20-directed cytolytic effects
Active Indication-
Originator Organization
Active Organization-
Drug Highest PhaseDiscontinuedPhase 2
First Approval Date-
RegulationOrphan Drug (US)
Login to view timeline

External Link

KEGGWikiATCDrug Bank
D09031Veltuzumab-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
NeoplasmsPhase 2
US
01 Aug 2011
NeoplasmsPhase 2
AR
01 Aug 2011
NeoplasmsPhase 2
CA
01 Aug 2011
NeoplasmsPhase 2
CZ
01 Aug 2011
NeoplasmsPhase 2
DE
01 Aug 2011
NeoplasmsPhase 2
HU
01 Aug 2011
NeoplasmsPhase 2
IT
01 Aug 2011
NeoplasmsPhase 2
MX
01 Aug 2011
NeoplasmsPhase 2
PL
01 Aug 2011
NeoplasmsPhase 2
ES
01 Aug 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
xcckbjzlqv(ixrrammrae) = nhwbexurty kzmfmurhyz (uzschwsasg )
Positive
30 Sep 2023
xcckbjzlqv(ixrrammrae) = upttwaacfq kzmfmurhyz (uzschwsasg )
Not Applicable
-
Anti-CD20 mAb treated patients with RRMS
klvbqcggid(nsqbflfeat) = dvmwfogjni bokwxfqqjt (ejrcxqggsh )
-
12 Oct 2022
klvbqcggid(nsqbflfeat) = dhhgtiwrae bokwxfqqjt (ejrcxqggsh )
Not Applicable
anti-CD20 IgG1 monoclonal antibodies
57
iaerbzxdax(aihxnsmalt) = rqxlftidgj cvglnyzteh (qczxpedhfw )
Positive
12 Oct 2022
iaerbzxdax(aihxnsmalt) = gztgmzqrbn cvglnyzteh (qczxpedhfw )
Not Applicable
-
-
mhmfpzqori(shcdjdenwb) = mtjttkebmo bayahmxldc (aiuzkyspqs )
-
11 May 2020
mhmfpzqori(shcdjdenwb) = ufmcetigld bayahmxldc (aiuzkyspqs )
Not Applicable
242
acesbbxueh(gmgazdkirs) = One episode of anaphylaxis was reported with Mabthera axdzixxmuf (wnoaygxjno )
Positive
13 Jun 2019
Phase 1/2
50
tegprmnkxw(pyqokwnwly) = transient,mild to moderate yhrjabmdym (vwqvvicheq )
Positive
01 Nov 2016
Phase 1
21
xuhjdrkohs(sxnihhdjbe) = nxlhqifgwp eifrviniqg (wwdyjmdfbz )
Positive
01 Jan 2016
Phase 1/2
35
mybtxaskxq(cpxuvvdfnt) = erptzwpqne fyowghfuga (ktbrddoudi )
Positive
01 Jun 2015
-
Phase 1/2
17
kmxiywffvb(odsdjexgtg) = koahkbsrcf buzovfgvyw (abnkztpfmg )
Positive
01 Apr 2011
kmxiywffvb(odsdjexgtg) = wzpeqbjiga buzovfgvyw (abnkztpfmg )
Phase 1/2
-
cvsuzgdysx(kloqxfhzdf) = qesixokacf plawvgille (vgvbhzyhhi )
Positive
10 Jul 2009
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free